Journal article icon

Journal article

Metabolomic consequences of genetic inhibition of PCSK9 compared with statin treatment

Abstract:

Background

Both statins and PCSK9 inhibitors lower blood low-density lipoprotein cholesterol (LDL C) levels to reduce risk of cardiovascular events. To assess potential differences between metabolic effects of these two lipid-lowering therapies, we performed detailed lipid and metabolite profiling ¬of a large randomized statin trial and compared the results with the effects of genetic inhibition of PCSK9, acting as a naturally occurring trial.

Methods

228 circulat...

Expand abstract
Publication status:
Published
Peer review status:
Peer reviewed
Version:
Publisher's Version

Actions


Access Document


Files:
Publisher copy:
10.1161/CIRCULATIONAHA.118.034942

Authors


More by this author
Institution:
University of Oxford
Division:
Medical Sciences Division
Department:
Nuffield Dept of Population Health
Subgroup:
Clinical Trial Service Unit
Role:
Author
Expand authors...
Academy of Finland More from this funder
University of Oulu More from this funder
Expand funders...
Publisher:
American Heart Association Publisher's website
Journal:
Circulation Journal website
Volume:
138
Issue:
22
Publication date:
2018-08-15
Acceptance date:
2018-07-17
DOI:
EISSN:
1524-4539
ISSN:
0009-7322
Pubs id:
pubs:926679
URN:
uri:66fc748e-32ea-467d-aedb-260991c63fbc
UUID:
uuid:66fc748e-32ea-467d-aedb-260991c63fbc
Local pid:
pubs:926679

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP